|
Participants, n (%)
|
9 (18.0)
|
7 (14.0)
|
23 (46.0)
|
11 (22.0)a
|
50 (100.0)
|
|
Female, n (%)
|
7 (14.0)
|
3 (6.0)
|
18 (36.0)
|
10 (20.0)
|
38 (76.8)
|
|
Age; median years (max-min)
|
30 (18 to 37)
|
31 (20 to 47)
|
37 (19 to 66)
|
29 (25 to 46)
|
32 (18 to 66)
|
|
Ethnicity, n (%)
| | | | | |
|
White
|
8 (16.0)
|
5 (10.0)
|
13 (26.0)
|
9 (18.0)
|
35 (70.0)
|
|
African American
|
0 (0.0)
|
1 (2.0)
|
4 (8.0)
|
1 (2.0)
|
6 (12.0)
|
|
Hispanic
|
0 (0.0)
|
0 (0.0)
|
3 (6.0)
|
0 (0.0)
|
3 (6.0)
|
|
Other
|
1 (2.0)
|
1 (2.0)
|
3 (6.0)
|
1 (2.0)
|
6 (12.0)
|
|
Atopic, n (%)
|
1 (2.0)
|
7 (14.0)
|
18 (36.0)
|
8 (16.0)
|
34 (68.0)
|
|
Baseline PC
20
; mean mg/mL (±SD)
|
28 (27.1)
|
6.7 (3.8)
|
4.5 (5.1)
|
4.4 (5.2)
|
n/a
|
|
Baseline FEV1; mean% predicted (±SD)
|
98.3 (11.0)
|
105.8 (6.7)
|
97.8 (16.5)
|
91.2 (10.8)
|
n/a
|
|
Medication, n (%)
| | | | | |
|
Inhaled corticosteroids
|
0 (0.0)
|
0 (0.0)
|
6 (12.0)
|
3 (6.0)
|
9 (18.0)
|
|
Inhaled corticosteroids plus long-acting beta agonists
|
0 (0.0)
|
0 (0.0)
|
2 (4.0)
|
1 (2.0)
|
3 (6.0)
|
|
Nasal steroids
|
0 (0.0)
|
0 (0.0)
|
6 (12.0)
|
3 (6.0)
|
9 (18.0)
|
|
Respiratory virus identification, n (%)
| | | | | |
|
Human rhinovirus
|
5 (10.0)
|
1 (2.0)
|
9 (18.0)
|
3 (6.0)
|
18 (36.0)
|
|
Respiratory syncytial virus
|
0 (0.0)
|
0 (0.0)
|
2 (4.0)
|
1 (2.0)b
|
3 (6.0)
|
|
Human coronavirus
|
1 (2.0)
|
1 (2.0)
|
2 (4.0)
|
2 (4.0)b
|
6 (12.0)
|
|
Influenza A virus
|
0 (0.0)
|
1 (2.0)
|
1 (2.0)
|
0 (0.0)
|
2 (4.0)
|
|
Human parainfluenza virus
|
0 (0.0)
|
1 (2.0)
|
0 (0.0)
|
0 (0.0)
|
1 (2.0)
|
|
No detection
|
3 (6.0)
|
3 (6.0)
|
9 (18.0)
|
5 (10.0)
|
20 (40.0)
|
